1. Home
  2. VLYPO vs TGTX Comparison

VLYPO vs TGTX Comparison

Compare VLYPO & TGTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Valley National Bancorp 5.50% Fixed-to-Floating Rate Non-Cumulative Perpetual Preferred Stock Series B

VLYPO

Valley National Bancorp 5.50% Fixed-to-Floating Rate Non-Cumulative Perpetual Preferred Stock Series B

N/A

Current Price

$24.88

Market Cap

0.0

Sector

Finance

ML Signal

N/A

Logo TG Therapeutics Inc.

TGTX

TG Therapeutics Inc.

HOLD

Current Price

$57.19

Market Cap

8.5B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
VLYPO
TGTX
Founded
N/A
1993
Country
United States
United States
Employees
N/A
N/A
Industry
Major Banks
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
N/A
8.5B
IPO Year
1994
2008

Fundamental Metrics

Financial Performance
Metric
VLYPO
TGTX
Price
$24.88
$57.19
Analyst Decision
Strong Buy
Analyst Count
0
5
Target Price
N/A
$49.80
AVG Volume (30 Days)
4.4K
1.8M
Earning Date
N/A
05-04-2026
Dividend Yield
N/A
N/A
EPS Growth
46.38
1746.67
EPS
0.57
0.17
Revenue
N/A
$2,785,000.00
Revenue This Year
N/A
$49.08
Revenue Next Year
N/A
$26.69
P/E Ratio
$43.64
$332.18
Revenue Growth
N/A
N/A
52 Week Low
$24.10
$26.76
52 Week High
$25.64
$59.30

Technical Indicators

Market Signals
Indicator
VLYPO
TGTX
Relative Strength Index (RSI) 42.73 60.38
Support Level $24.52 $51.51
Resistance Level $25.04 $58.12
Average True Range (ATR) 0.15 2.26
MACD -0.03 0.06
Stochastic Oscillator 29.63 81.68

Price Performance

Historical Comparison
VLYPO
TGTX

About VLYPO Valley National Bancorp 5.50% Fixed-to-Floating Rate Non-Cumulative Perpetual Preferred Stock Series B

Valley National Bancorp is a bank holding company that offers a full suite of national and regional banking solutions through various commercial, private banking, retail, insurance, and wealth management financial services products. It provides personalized service and customized solutions to assist its customers with their financial service needs. The group also offers niche financial services, including loan and deposit products for homeowners associations, cannabis-related business banking, and venture banking, which offers nationally. It manages its business operations under operating segments consisting of Consumer Banking; Commercial Banking; and Treasury and Corporate Other. The group generates the majority of its revenue from the Commercial Banking Segment.

About TGTX TG Therapeutics Inc.

TG Therapeutics Inc is a fully integrated, commercial-stage biotechnology company focused on acquiring, developing, and commercializing novel treatments for B-cell diseases. In addition to a research pipeline, TG Therapeutics has received approval from the U.S. Food and Drug Administration (FDA) for BRIUMVI (ublituximab-xiiy) to treat adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, as well as approval from several regulatory agencies outside of the U.S. for BRIUMVI to treat adult patients with RMS who have active disease defined by clinical or imaging features.

Share on Social Networks: